[Danaparoid for anticoagulation with Cell Saver 5. Answer to the letter of A. Lorentz].
von Lüpke
U
U
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001804:Blood Transfusion, Autologous / Q000295:instrumentation*; D002809:Chondroitin Sulfates / Q000009:adverse effects / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D006497:Heparan Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006497:Heparan Sulfate; C035838:danaparoid